Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) FCF Margin (2023 - 2025)

CG Oncology filings provide 3 years of FCF Margin readings, the most recent being 1558.01% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 301896.0% to 1558.01% in Q4 2025 year-over-year; TTM through Dec 2025 was 3278.07%, a 365319.0% increase, with the full-year FY2025 number at 3278.07%, up 365319.0% from a year prior.
  • FCF Margin hit 1558.01% in Q4 2025 for CG Oncology, up from 2342.56% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1558.01% in Q4 2025 to a low of 1464500.0% in Q4 2023.
  • Median FCF Margin over the past 3 years was 9727.3% (2024), compared with a mean of 172614.44%.
  • Biggest five-year swings in FCF Margin: skyrocketed 145992303bps in 2024 and later crashed -5141322bps in 2025.
  • CG Oncology's FCF Margin stood at 1464500.0% in 2023, then soared by 100bps to 4576.97% in 2024, then surged by 66bps to 1558.01% in 2025.
  • The last three reported values for FCF Margin were 1558.01% (Q4 2025), 2342.56% (Q3 2025), and 56332.69% (Q1 2025) per Business Quant data.